Torrent Pharma launches medicines for treatment of metabolic disorders
Ahmedabad, March 21: Torrent Pharmaceuticals has launched Semaglutide brands – Sembolic and Semalix – in India, expanding the company’s presence in metabolic disorders such as type-2 diabetes and obesity.
These medicines will be available in both oral and injectable formulations, the company said.
Commenting on the launch, Amal Kelshikar, CEO – India Business, Torrent Pharma, said: “Metabolic disorders represent one of the most significant healthcare challenges in India with a significant portion of our population affected by Type-2 Diabetes. Our entry into the GLP-1 therapy segment reflects Torrent’s commitment to expanding treatment options available to healthcare professionals managing complex metabolic conditions at affordable prices.
About GLP-1 Drug Category
GLP-1 (glucagon-like peptide-1) receptor agonists are well-established prescription medications for the management of type 2 diabetes and obesity. They work by enhancing insulin secretion, reducing glucagon levels and help regulate appetite. They have been shown to be effective at decreasing haemoglobin A1c (HbA1c), promoting weight loss and reducing the risk of cardiovascular events by mimicking the hormone GLP-1
About Torrent Pharmaceuticals Limited
Torren Pharma, with annual revenues of more than Rs 11,500 crores, is the flagship Company of the Torrent Group, with group revenues of ~Rs 45,000 crores. Post JB Pharma acquisition it is ranked 5th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), Pain Management and Cosmo-Dermatology.
